Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_097405822d505467fd50f7100022cd56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_73d55b44219a84c850812a4488def924 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A90-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-28 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6896 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6848 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N27-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H50-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H50-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6818 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6851 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N27-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16H50-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16H50-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
filingDate |
2017-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2022-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17da8e201946c4131764b571dc994a1d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_729fde92daf31eef08cd5829cdf13df5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_81605257b99986cdf3d053862f053fe2 |
publicationDate |
2022-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-11313862-B2 |
titleOfInvention |
Method for diagnosing amyotrophic lateral sclerosis using signal peptide as indicator |
abstract |
The method for aiding ALS detection provided by the present invention includes determining a profile of signal peptides contained in a bodily fluid from a test subject, and comparing the signal peptide profile thus determined for the test subject with a previously-determined profile of signal peptides in a bodily fluid from a healthy subject. The presence of a difference between the signal peptide profile of the test subject and the signal peptide profile of the healthy subject at a specific molecular weight is then associated with the test subject's suffering from or developing ALS. |
priorityDate |
2016-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |